Remdesivir
Pronunciation
(rem DE si vir)
Index Terms
- GS-5734
Pharmacologic Category
- Antiviral Agent
Pharmacology
Inhibition of RNA synthesis (Agostini 2018).
Off Label Uses
Coronavirus disease 2019
In vitro and animal studies demonstrate the activity of remdesivir against coronaviruses (eg, severe acute respiratory syndrome coronavirus [SARS-CoV], SARS-CoV-2, Middle East respiratory syndrome coronavirus) [Agostini 2018], [Sheahan 2017], [Sheahan 2020], [Wang 2020]. A single case report describes clinical improvement after receipt of remdesivir in a patient infected with SARS-CoV-2 whose clinical status was worsening prior to receiving the drug; however, no conclusions about the safety and efficacy of remdesivir in this case can be made [Holshue 2020].
Dosing: Adult
Coronavirus disease 2019: IV: Limited data available; dosing used in clinical trials: 200 mg as a single dose on day 1, followed by 100 mg once daily for a total duration of 5 to 10 days (Gilead 2020; NIH 2020a; NIH 2020b; NIH 2020c).
Dosing: Geriatric
Refer to adult dosing.
Dosing: Pediatric
Coronavirus infection: Note: Initial trials have been limited to patients ≥18 years of age.
Adolescents ≥18 years: IV: Limited data available; dosing used in ongoing clinical trials: 200 mg as a single dose on day 1, followed by 100 mg once daily for a total duration of 5 to 10 days (Gilead 2020; NIH 2020a; NIH 2020b; NIH 2020c).
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
